Katarzyna Głuszek

Katarzyna Głuszek

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2015 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
Ewelina PiktelEwelina Piktel
Ewelina Piktel
KNKatarzyna Niemirowicz
Katarzyna Niemirowicz
Urszula WnorowskaUrszula Wnorowska
Urszula Wnorowska
MWMarzena Wątek
Marzena Wątek
TWTomasz Wollny
Tomasz Wollny
RBRobert Bucki
Robert Bucki
LL-37 is a C-terminal peptide proteolytically released from 18 kDa human cathelicidin protein (hCAP18). Chronic infections, inflammation, tissue injury and tissue regeneration are all linked with neoplastic growth, and involve LL-37 antibacterial and immunomodulatory functions. Such a link points to the possible involvement of LL-37 peptide in carcinogenesis. An increasing amount of evidence suggests that LL-37 can have two different and contradictory effects—promotion or inhibition of tumor growth. The mechanisms are tissue-specific, complex, and depend mostly on the ability of LL-37 to act as a ligand for different membrane receptors whose expression varies on different cancer cells. Overexpression of LL-37 was found to promote development and progression of ovarian, lung and breast cancers, and to suppress tumorigenesis in colon and gastric cancer. This review explores and summarizes the current views on how LL-37 contributes to immunity, pathophysiology and cell signaling involved in malignant tumor growth.

1 November 2016 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
KNKatarzyna Niemirowicz
Katarzyna Niemirowicz
BDBonita Durnaś
Bonita Durnaś
GTGrażyna Tokajuk
Grażyna Tokajuk
KGKatarzyna Głuszek
Katarzyna Głuszek
Agnieszka WilczewskaAgnieszka Wilczewska
Agnieszka Wilczewska
RBRobert Bucki
Robert Bucki

18 December 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ALAgata Lesiak
Agata Lesiak
PPPaulina Paprocka
Paulina Paprocka
UWUrszula Wnorowska
Urszula Wnorowska
AMAngelika Mańkowska
Angelika Mańkowska
GKGrzegorz Król
Grzegorz Król
RBRobert Bucki
Robert Bucki
Acne vulgaris (AV) is a chronic inflammatory condition of the pilosebaceous units characterized by multiple immunologic, metabolic, hormonal, genetic, psycho-emotional dysfunctions, and skin microbiota dysbiosis. The latter is manifested by a decreased population (phylotypes, i.e., genetically distinct bacterial subgroups that play different roles in skin health and disease) diversity of the predominant skin bacterial commensal - Cutinbacterium acnes. Like in other dysbiotic disorders, an elevated expression of endogenous antimicrobial peptides (AMPs) is a hallmark of AV. AMPs, such as human β-defensins, cathelicidin LL-37, dermcidin, or RNase-7, due to their antibacterial and immunomodulatory properties, function as the first line of defense and coordinate the host-microbiota interactions. Therefore, AMPs are potential candidates for pharmaceutical prophylaxis or treating this condition. This study outlines the current knowledge regarding the importance of AMPs in AV pathomechanism in light of recent transcriptomic studies. In particular, their role in improving the tight junctions (TJs) skin barrier by activating the fundamental cellular proteins, such as PI3K, GSK-3, aPKC, and Rac1, is discussed. We hypothesized that the increased expression of AMPs and their patterns in AV act as a compensatory mechanism to protect the skin with an impaired permeability barrier. Therefore, AMPs could be key determinants in regulating AV development and progression, linking acne-associated immune responses and metabolic factors, like insulin/IGF-1 and PI3K/Akt/mTOR/FoxO1 signaling pathways or glucotoxicity. Research and development of anti-acne AMPs are also addressed.

1 June 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
KNKatarzyna Niemirowicz-Laskowska
Katarzyna Niemirowicz-Laskowska
KGKatarzyna Głuszek
Katarzyna Głuszek
Ewelina PiktelEwelina Piktel
Ewelina Piktel
KPKarlis Pajuste
Karlis Pajuste
BDBonita Durnaś
Bonita Durnaś
RBRobert Bucki
Robert Bucki
Background: 1,4-Dihydropyridine (1,4-DHP) and its derivatives are well-known calcium channel blockers with antiarrhythmic and antihypertensive activities. These compounds exhibit pleiotropic effects including antimicrobial activities that rely on their positive charge and amphipathic nature. Use of magnetic nanoparticles (MNPs) as carriers of 1,4-DHP modulates their properties and enables improved formulations with higher efficacy and less toxicity. Methods: In this study, the antimicrobial and immunomodulatory activities of novel 1,4-DHP derivatives in free form and immobilized on MNPs were determined by evaluating pathogen outgrowth and proinflammatory cytokine release in experimental settings that involve incubation of various 1,4-DHPs with clinical isolates of bacteria or fungi as well as mammalian cell culture models. Results: Conventional immobilization of 1,4-DHP on aminosilane-coated MNPs markedly enhances their antimicrobial activity compared to nonimmobilized molecules, in part because of the higher affinity of these nanosystems for bacterial cell wall components in the presence of human body fluids. Conclusion: Optimized nanosystems are characterized by improved biocompatibility and higher anti-inflammatory properties that provide new opportunities for the therapy of infectious diseases.

10 November 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
UWUrszula Wnorowska
Urszula Wnorowska
EPEwelina Piktel
Ewelina Piktel
PDPiotr Deptuła
Piotr Deptuła
TWTomasz Wollny
Tomasz Wollny
GKGrzegorz Król
Grzegorz Król
RBRobert Bucki
Robert Bucki
Ceragenins (CSAs) are synthetic, lipid-based molecules that display activities of natural antimicrobial peptides. Previous studies demonstrated their high in vitro activity against pathogens causing urinary tract infections (UTIs), but their efficiency in vivo was not explored to date. In this study, we aimed to investigate the bactericidal efficiency of ceragenins against E. coli (Xen14 and clinical UPEC strains) isolates both in vitro and in vivo, as well to explore CSA-13 biodistribution and ability to modulate nanomechanical alterations of infected tissues using animal model of UTI. CSA-44, CSA-131 and particularly CSA-13 displayed potent bactericidal effect against tested E. coli strains, and this effect was mediated by induction of oxidative stress. Biodistribution studies indicated that CSA-13 accumulates in kidneys and liver and is eliminated with urine and bile acid. We also observed that ceragenin CSA-13 reverses infection-induced alterations in mechanical properties of mouse bladders tissue, which confirms the preventive role of CSA-13 against bacteria-induced tissue damage and potentially promote the restoration of microenvironment with biophysical features unfavorable for bacterial growth and spreading. These data justify the further work on employment of CSA-13 in the treatment of urinary tract infections.

26 May 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
PPPaulina Paprocka
Paulina Paprocka
AMAngelika Mańkowska
Angelika Mańkowska
KSKarol Skłodowski
Karol Skłodowski
GKGrzegorz Król
Grzegorz Król
TWTomasz Wollny
Tomasz Wollny
RBRobert Bucki
Robert Bucki
Background: Stenotrophomonas maltophilia (S. maltophilia) is an emerging opportunistic Gram-negative rod causing nosocomial infections predominantly in immunocompromised patients. Due to its broad intrinsic resistance to antibiotics, including carbapenems and the ability to form a biofilm, it is difficult to eradicate. Methods: In this study, the benefit of combined administration (potential synergism) and anti-biofilm activity of ceragenins: CSA-13, CSA-44, and CSA-131 (synthetic mimics of natural antimicrobial peptides) with ceftazidime, levofloxacin, co-trimoxazole and colistin against clinical strains of S. maltophilia were determined using MIC/MBC (minimum inhibitory concentration/minimum bactericidal concentration), killing assays and CV staining. Results: Obtained data indicate that the ceragenins exhibit strong activity against the tested strains of S. maltophilia grown in planktonic culture and as stationary biofilms. Moreover, with some strains, the synergy of ceragenins with conventional antibiotics was observed Conclusion: Our data suggest that ceragenins are promising agents for future development of new methods for treatment of infections caused by S. maltophilia, along with its potential use in combination with conventional antibiotics.